GlassScriptPhysician profile
Ralitza T Martin
NPI 1306011739
$47,539.96
in general payments reported to CMS, 2019-2025
32 companies · $8,322 in 2025
The $8,322 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,595 · 2020: $2,813 · 2021: $2,164 · 2022: $18K · 2023: $9,847 · 2024: $4,375 · 2025: $8,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $2,512 · Travel and Lodging: $1,254 · Consulting Fee: $400 · Gift: $10.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,367.50 |
| Food and Beverage | $2,511.69 |
| Travel and Lodging | $1,254.40 |
| Consulting Fee | $400.00 |
| Gift | $10.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $19,473.17 | 2020-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Pulmonx Corporation | $18,381.43 | 2019-2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Cook Incorporated | $8,367.50 | 2022-2025 | Melker |
| Astrazeneca Pharmaceuticals LP | $149.45 | 2023-2024 | Imfinzi, Tezspire |
| Janssen Biotech, INC. | $141.08 | 2025 | Rybrevant |
| Cook Medical LLC | $121.76 | 2020-2025 | Blue Rhino |
| Glaxosmithkline, LLC. | $100.70 | 2019-2025 | Trelegy Ellipta, Nucala |
| Pfizer INC. | $77.53 | 2019-2024 | |
| Insmed, INC. | $76.71 | 2023-2024 | Arikayce |
| Novartis Pharmaceuticals Corporation | $51.70 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.00 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $48.95 | 2019 | |
| Philips North America LLC | $45.90 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Actelion Pharmaceuticals US, INC. | $38.44 | 2022-2023 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $37.30 | 2024 | Dupixent |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Medical Corporation | $33.07 | 2020 | |
| Mylan Specialty L.P. | $31.30 | 2019-2023 | Yupelri |
| Healthmyne, INC. | $30.00 | 2019 | |
| Olympus America INC. | $29.88 | 2020-2021 | |
| Ambu INC. | $28.02 | 2020 | |
| Csl Behring | $27.95 | 2024 | Hizentra |
| Lilly USA, LLC | $25.16 | 2025 | Zepbound |
| Advanced Respiratory, INC | $22.79 | 2019 | |
| Viatris Specialty LLC | $21.04 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $19.79 | 2023 | Belsomra |
| Genzyme Corporation | $18.78 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.54 | 2023 | |
| Grifols USA, LLC | $16.23 | 2025 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $15.46 | 2022 | |
| Abbott Laboratories | $14.93 | 2019 | |
| Resmed Corp | $13.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralitza Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.